To All BioLab Distributors and Stakeholders,

I hope this message finds you well. We would like to share an important update regarding the availability and manufacturing strategy for certain skin substitute products offered by Biolab Holdings. Following a comprehensive internal review, analysis of historical utilization data, and recent Medicare updates, BioLab Holdings will be refining its skin substitute portfolio effective January 1st, 2026. This decision allows us to better align production with clinical demand while continuing to support providers and patients across the continuum of care. 

BioLab Holdings will make available Membrane Wrap - Lite™ in the 6x8cm size and Membrane Wrap™ in the following sizes: 2x3cm, 4x4cm, 4x6cm, 4x8xm, and 6x8cm. In addition, BioLab Holdings will continue to make available Microlyte® SAM™ in the following sizes: 3x3cm, 4x4cm, 5x5cm, 6x8cm, and 10x10cm.

These changes are being implemented to meet the increasing demands of our customer base. BioLab Holdings continues to work diligently to identify cost-containment measures within our manufacturing processes to support the evolving needs and challenges of our customers and providers. 

 
Skin substitutes remain an important part of our portfolio, and we are committed to ensuring that providers and patients continue to have access to effective and clinically meaningful treatment options. 

​

BioLab Holdings will continue to monitor market dynamics, reimbursement updates, and patient and provider needs and may adjust product offerings in the future as necessary. 

​

We appreciate your continued partnership, understanding, and trust. Please do not hesitate to reach out if you have any questions or require additional clarification. 

​

Thank you for your continued dedication to our mission. 

Best regards,

Jaime Leija
President, CEO, & Co-Founder
BioLab Holdings